1. Medtech Insight
  2. >>Archive

Ireland reiterates Access CardioSystems AEDs recall

Irish healthcare providers are being urged to replace "as soon as possible" any defibrillators manufactured by Access CardioSystems (ACS), in a notice that reiterates the company's and the Irish Medicines Board's (IMB) November 15 alert relating to the recall of certain batches of ACS' Access AED PAD, Access AED and Access ALS devices. The IMB emphasises that ACS has discontinued support for all its devices and that "orders for disposable parts will no longer be accepted" since the company recently ceased trading.

Irish healthcare providers are being urged to replace "as soon as possible" any defibrillators manufactured by Access CardioSystems (ACS), in a notice that reiterates the company's and the Irish Medicines Board's (IMB) November 15 alert relating to the recall of certain batches of ACS' Access AED PAD, Access AED and Access ALS devices. The IMB emphasises that ACS has discontinued support for all its devices and that "orders for disposable parts will no longer be accepted" since the company recently ceased trading.

Medical Device Consultants International (Crawley, West Sussex, UK), the European subsidiary of Medical Device Consultants (North Attleboro, Massachusetts) is ACS'...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 
• By Brian Bossetta

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.

Edwards Lifesciences Lowers Tariff Impact Forecast, Keeps Gross Margin Guidance Intact

 
• By Shubham Singh

The company reaffirmed its guidance for adjusted gross profit margin for the full year 2025 to remain within the original range of 78% to 79%. Chief financial officer Scott Ullem attributed this to currency and tariff dynamics.

Olympus, Revival Co-Found Swan In $458M Deal, Face Tech and Regulatory Hurdles

 
• By Marion Webb

Olympus and Revival Healthcare Capital have launched Swan Endosurgical in a $458m milestone-based joint venture to develop a robotic platform for endoluminal surgery. The deal combines Olympus’ GI expertise with Revival’s start-up model, but will face technical and regulatory hurdles.